miRNAs in cerebrospinal fluid associated with Alzheimer's disease: A systematic review and pathway analysis using a data mining and machine learning approach
- PMID: 38390627
- DOI: 10.1111/jnc.16060
miRNAs in cerebrospinal fluid associated with Alzheimer's disease: A systematic review and pathway analysis using a data mining and machine learning approach
Abstract
Alzheimer's disease (AD) is the most common type and accounts for 60%-70% of the reported cases of dementia. MicroRNAs (miRNAs) are small non-coding RNAs that play a crucial role in gene expression regulation. Although the diagnosis of AD is primarily clinical, several miRNAs have been associated with AD and considered as potential markers for diagnosis and progression of AD. We sought to match AD-related miRNAs in cerebrospinal fluid (CSF) found in the GeoDataSets, evaluated by machine learning, with miRNAs listed in a systematic review, and a pathway analysis. Using machine learning approaches, we identified most differentially expressed miRNAs in Gene Expression Omnibus (GEO), which were validated by the systematic review, using the acronym PECO-Population (P): Patients with AD, Exposure (E): expression of miRNAs, Comparison (C): Healthy individuals, and Objective (O): miRNAs differentially expressed in CSF. Additionally, pathway enrichment analysis was performed to identify the main pathways involving at least four miRNAs selected. Four miRNAs were identified for differentiating between patients with and without AD in machine learning combined to systematic review, and followed the pathways analysis: miRNA-30a-3p, miRNA-193a-5p, miRNA-143-3p, miRNA-145-5p. The pathways epidermal growth factor, MAPK, TGF-beta and ATM-dependent DNA damage response, were regulated by these miRNAs, but only the MAPK pathway presented higher relevance after a randomic pathway analysis. These findings have the potential to assist in the development of diagnostic tests for AD using miRNAs as biomarkers, as well as provide understanding of the relationship between different pathophysiological mechanisms of AD.
Keywords: Alzheimer's disease; biomarkers; cerebrospinal fluid; machine learning; miRNAs.
© 2024 International Society for Neurochemistry.
References
REFERENCES
-
- Akao, Y., Nakagawa, Y., & Naoe, T. (2006). MicroRNAs 143 and 145 are possible common onco‐microRNAs in human cancers. Oncology Reports, 16(4), 845–850.
-
- Alam, J., Blackburn, K., & Patrick, D. (2017). Neflamapimod: Clinical phase 2b‐ready oral small molecule inhibitor of p38α to reverse synaptic dysfunction in early Alzheimer's disease. The Journal of Prevention of Alzheimer's Disease, 4(4), 273–278. https://doi.org/10.14283/jpad.2017.41
-
- Alexandrov, P. N., Dua, P., Hill, J. M., Bhattacharjee, S., Zhao, Y., & Lukiw, W. J. (2012). microRNA (miRNA) speciation in Alzheimer's disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). International Journal of Biochemistry and Molecular Biology, 3(4), 365–373.
-
- Anvar, N. E., Saliminejad, K., Ohadi, M., Kamali, K., Daneshmand, P., & Khorshid, H. R. K. (2015). Association between polymorphisms in Interleukin‐16 gene and risk of late‐onset Alzheimer's disease. Journal of the Neurological Sciences, 358(1–2), 324–327. https://doi.org/10.1016/j.jns.2015.09.344
-
- Aouadi, M., Bost, F., Caron, L., Laurent, K., Le Marchand Brustel, Y., & Binétruy, B. (2006). p38 mitogen‐activated protein kinase activity commits embryonic stem cells to either neurogenesis or cardiomyogenesis. Stem Cells, 24(5), 1399–1406.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
